the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients

Recruiting now · Phase 2

Conditions studied: Heart Failure

In brief

the study to investigate the efficacy of empagiflozin in pediatric heart failure

Key facts

Study ID

NCT07692256

Run by

Ain Shams University

People needed

60

Starts

2025-12-01

Expected to finish

2027-02-01

Last updated by the study team

2026-07-09

Who can join

Age: 0 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• • Pediatrics (aged 1months-18 years)
• Confirmed HF diagnosis:
• HF will be defined by reduced ventricular systolic function (left ventricular ejection fraction by echocardiography) or impaired ventricular filling (pulmonary capillary wedge pressure > 18 mmHg measured directly and/or the ratio of early diastolic mitral inflow velocity(E) to early diastolic mitral annular velocity (e')( E/e'>14 by echocardiography) with clinical features of congestion and/or low cardiac output.
• Class III or IV of ROSS classification or BNP level more than 300 pg/mL

You may not qualify if…

• • Pediatric with chronic kidney failure
• Avoid initiating empagliflozin in patients with concurrent urinary tract infection (UTI).
• patients with eGFR <60 mL/minute/1.73 m2 will be excluded.
• Patients with contraindication to empagliflozin usage which include
• eGFR <30 mL/minute/1.73 m2
• Hypersensitivity (eg, angioedema) to empagliflozin

Where it is running

• Ain Shams Hospital — Cairo, Cairo Governorate, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.